Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Hemogenyx Pharmaceuticals outlines significant progress with HEMO-CAR-T in 2023

HemoGenyx Pharmaceuticals

Hemogenyx Pharmaceuticals PLC CEO Dr Vladislav Sandler tells Proactive's Stephen Gunnion that 2023 was a significant year for the company, marked by notable progress with its HEMO-CAR-T product candidate. The key achievement for the year was the submission of a new Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to commence a phase one clinical trial for the treatment of relapsed refractory acute myeloid leukemia. However, the process faced a setback due to issues with lentivirus purity, resulting in a clinical hold. After re-manufacturing the lentivirus, Hemogenyx successfully addressed the FDA's concerns and received approval to proceed with the clinical trials. Furthermore, Sandler reported a successful fundraising which will support the upcoming clinical studies. The company also entered a service agreement with Prevail Infoworks for the clinical trials. In addition to its advancements in HEMO-CAR-T, Hemogenyx continued developing other programs, such as its proprietary Chimeric Bait Receptor (CBR) platform, showing promise in treating non-Hodgkin lymphoma and exploring applications in solid rare tumors. For 2024, the primary focus remains on advancing these clinical trials, particularly the phase one studies, with an immediate goal to initiate patient treatment. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 29, 2024 11:52 AM Eastern Daylight Time

Video

Immunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial role

Immunic Inc

Immunic Inc CEO Dr Daniel Vitt joins Proactive's Stephen Gunnion on the International Day of Immunology to discuss the broad and crucial role of immunology in human health. Vitt said immunology encompasses immune responses against pathogens like viruses, including the coronavirus, and also plays a significant role in combating cancer. He highlighted the importance of the immune system in managing and preventing autoimmune diseases, where the body mistakenly attacks its own cells, leading to various conditions. Focusing on Immunic's efforts, Vitt detailed their drug development pipeline, particularly in addressing chronic inflammatory and autoimmune diseases such as multiple sclerosis, ulcerative colitis, Crohn's disease, and celiac disease. He spotlighted multiple sclerosis, with ongoing phase three studies in its relapsing form and a phase two study, named the CALLIPER trial, for its progressive form. The latter holds particular promise as it targets an area with currently no available treatments. For celiac disease, Vitt reported promising results from a phase one B proof-of-concept study that showed positive data across various metrics, including histology and biomarker levels. Plans are underway for further phase two studies in celiac disease and potentially other indications. Vitt also shared his personal journey from chemistry to immunology, driven by the potential to develop drugs that address significant medical needs. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

April 29, 2024 11:11 AM Eastern Daylight Time

Video

New Standard of Care? IceCure Submits Final ICE3 Data To FDA, Minimally Invasive Cryoablation Shows Similar 5-year Recurrence Outcomes To Surgery With Hormone Therapy

Benzinga

By Meg Flippin, Benzinga IceCure Medical Ltd. (NASDAQ: ICCM), the Israeli medical device developer of ProSense®, an advanced liquid-nitrogen-based cryoablation therapy that destroys tumors (benign and cancerous) by freezing them, is one step closer to getting U.S. Food and Drug Administration approval to market ProSense® to treat patients with early-stage T1 invasive breast cancer with cryoablation and adjuvant hormone therapy. IceCure just reported final clinical trial results of 100% patient and physician satisfaction with the minimally invasive procedure. At the 5-year follow-up evaluation, 96.3% of the subgroup of patients treated with ProSense® cryoablation, followed by hormone therapy, were estimated to be free from local recurrence Earlier in April, the company submitted its final data to the FDA which included five-year follow-up data from its ICE3 study, a sub-analysis of the ICE3 results compared to studies that evaluated the risk of recurrence in patients with low-risk Luminal A breast cancer who were treated with lumpectomy surgery and received hormone therapy and real-world data from the use of ProSense® globally, including post-market commercial use as well as data from independent third-party studies. ProSense®, which received the FDA's Breakthrough Device Designation, is already cleared for use in the U.S. for several other indications, including treating benign tumors of the breast and tumors in the kidney and liver. Positive Topline Results IceCure’s ICE3 study was the largest controlled multicenter clinical trial ever performed for liquid nitrogen (LN2) based cryoablation of low-risk, early-stage malignant breast tumors. The five-year recurrence-free rates from the study, which evaluated IceCure's minimally invasive 20-to-40-minute outpatient cryoablation procedure, were in line with expectations and showed similar outcomes to lumpectomy, the current standard of care for early-stage breast cancer patients, which is breast surgery that requires an operating room and hospital stay. In the ICE3 study, 96.39% of patients (187 out of 194 patients) were local recurrence-free with no significant device-related adverse events or complications reported. A comparison of this result from the ICE3 study shows similar outcomes in five-year recurrence rates compared to patients in other studies who were treated with lumpectomy followed by hormone therapy. The LUMINA study reported a 97.7% recurrence-free rate at five-year follow-up and the PRISMA meta-study, which included Lumina, reported a 97.19% recurrence-free rate at five-year follow-up. ICE3 results are also in line with data from real-world use of ProSense® by third parties in territories where IceCure's cryoablation system is used to treat early-stage breast cancer. In the final ICE3 analysis, no significant device-related adverse events or complications were reported, and all patients and physicians reported satisfaction with the ProSense® procedure, the company said. That means 100% of physicians and patients were happy with the treatments they received. Dr. Richard Fine, ICE3’s lead investigator, presented final data from the ICE3 study at the American Society of Breast Surgeons 25th Annual Meeting, where he commented, "Cryoablation is a safe, minimally invasive ablative procedure with acceptably low five-year same breast recurrence similar to that of lumpectomy for similar patient populations, with the benefit of being an office-based, nonsurgical treatment. Further study within a clinical trial or registry is needed to confirm cryoablation as a viable alternative to surgical excision in the appropriately selected patients.” Dr. Fine’s presentation, which received the conference’s Scientific Impact Award, was well received by breast surgeons who are constantly looking for treatments that are minimally invasive and effective. A New Way To Treat An Old Problem What makes cryoablation so attractive to freeze and destroy tumors is that it is minimally invasive, has little pain associated with it and thanks to an ultrasound or computerized tomography can accurately destroy diseased tissue within the tumor zone. Cryoablation also costs less than a lumpectomy and reduces the risk of follow-up surgery. With a lumpectomy, the re-excision rate is between 14-21%. IceCure’s ProSense® has the potential to become a new standard of care treatment for women with early-stage T1 invasive breast cancer, marking a major improvement to the care available today. Some researchers have even called cryoablation the “ ultimate esthetic solution for breast cancer ” because it reduces the need for pre-emptive or corrective surgical procedures to maintain or restore breast volume, contour and symmetry. "Initial reimbursement codes are already in place and our U.S. marketing and commercial team is ready, as we await the FDA's response. Driven by favorable healthcare economics combined with patient satisfaction and demand, we expect rapid adoption pending FDA granting the DeNovo Classification Request for Marketing Approval," stated IceCure CEO Eyal Shamir. With Reimbursement In Place, IceCure Is Ready To Go With the final data submitted, IceCure is ready to go once the FDA gives it the green light. The company received what it said was the first Medicare coverage approval of a cryoablation procedure for breast cancer. The Centers for Medicare & Medicaid Services (CMS) set the reimbursement payment at about $3,400 for the facility alone. Additional coverage, including payment for the physician, is expected upon establishment of the permanent CPT Category I code, which is conditioned on factors including the company's receipt of FDA marketing authorization of ProSense® for breast cancer. Having that reimbursement should enhance the usage of the ProSense® system. Nearly 300,000 women are diagnosed with invasive breast cancer yearly, and the majority have to undergo invasive treatments and deal with follow-up surgeries in the quest to live cancer-free. IceCure is changing that by freezing tumors to destroy them. IceCure seems poised to do exactly what it set out to do: provide women with an alternative minimally invasive treatment option. Featured photo by Angiola Harry on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

April 29, 2024 08:20 AM Eastern Daylight Time

Image

AI Frontiers in Healthcare: Revolutionizing Medicine at the 2024 1ArtificialIntelligence Global Conference

1BusinessWorld

As the healthcare sector undergoes a technological transformation, artificial intelligence (AI) is at the forefront, driving significant advancements. The 1ArtificialIntelligence | 2024 Global AI Conference will delve into these developments during its standout session, " Breaking New Ground: How AI and Tech Startups Are Revolutionizing the Digital Health Landscape. " Scheduled for May 9, this pivotal discussion promises to highlight the innovative role of AI in reshaping healthcare delivery and management. Moderated by Sally Ann Frank, Worldwide Lead for Health & Life Sciences, Microsoft for Startups, this panel brings together industry luminaries who are pioneering the integration of AI into healthcare. The session features: - Sally Ann Frank, WW Lead, Health & Life Sciences, Microsoft for Startups - Stead Burwell, Founder & CEO, Outbound AI - Lana Feng, Co-founder and CEO, Huma.Al - Andrew Gostine, CEO, Artisight - Ankur Teredesai, CEO, CueZen These experts are set to discuss the transformative impact of AI across various aspects of healthcare: - AI-Driven Diagnostics and Personalized Treatment: The panel will explore how AI is enhancing diagnostic accuracy and enabling personalized treatment plans that are tailored to individual patient needs. - Operational Efficiency: Insights will be shared on how AI is streamlining operations within healthcare facilities, from administrative processes to patient care, reducing costs and improving service delivery. - Ethical and Regulatory Frameworks: As AI becomes more entrenched in healthcare, the panelists will tackle the ethical considerations and regulatory challenges that need to be navigated to ensure responsible deployment of AI technologies. The discussion is not just about what AI is currently achieving but also about its future potential. The panelists will provide forecasts on emerging technologies, anticipated regulatory developments, and the long-term implications of AI in healthcare. This session will serve as a comprehensive guide for healthcare professionals, technology innovators, and policymakers interested in the intersection of AI and healthcare. For those looking to stay at the cutting edge of healthcare innovation, the "Breaking New Ground" session at the 1ArtificialIntelligence | 2024 Global AI Conference is an unmissable event. It offers a unique opportunity to hear from the trailblazers who are not only navigating the challenges of AI integration but are also setting the stage for the next generation of healthcare solutions. Contact Details Media Enquiries +1 212-220-6677 info@1businessworld.com Company Website https://1businessworld.com

April 28, 2024 03:17 PM Eastern Daylight Time

Image

AmeriLife’s The Senior Resource Group Partners with Bobby Brock Insurance and Camas Prairie Insurance to Transform Medicare Choice

AmeriLife

The Senior Resource Group, (SRG), a leading, national field marketing organization (FMO) for the industry’s leading insurance carriers and an affiliate of AmeriLife Group, LLC (“AmeriLife”), announced today that it has entered into a partnership with Bobby Brock Insurance (BBI), a leading national health insurance agency and founding sponsor of MedicareCon, a highly regarded annual Medicare and health insurance conference for licensed and entrepreneurial health insurance agents. In a separate but related deal, SRG also welcomed Camas Prairie Insurance (CPI), a central Idaho-based, family owned and operated health insurance agency and downline partner of Bobby Brock Insurance (which will continue to operate as such). Per both agreements, terms were not disclosed. “We are so excited to partner with the Bobby Brock Insurance and Camas Prairie Insurance teams,” said Shane Souders, co-founder of The Senior Resource Group. “[BBI CEO] Justin is a trusted voice for the Medicare broker community and an incredible business leader, while [CPI owner] Josh Lustig is a great young leader and one of the best sales trainers and motivators in the business today. SRG, BBI and CPI, with the support of AmeriLife, are aligned with complementary skillsets that will make us one of the most dynamic Medicare agency partnerships in the country.” Founded by Bobby Brock in 1992, Bobby Brock Insurance operates as a national brokerage firm and call center that specializes in ACA plans for the under-65 market, Medicare Supplement plans, Medicare Part D plans, and Medicare Advantage. In 2014, Bobby Brock’s son and the company’s current CEO, Justin Brock, left the Marine Corps to pursue a career as a licensed Medicare agent. The younger Brock saw a need to breathe fresh air into the marketing, service, and team building aspect of the industry, and quickly established a thriving culture and expanded value proposition for both agents and consumers with the concepts he learned as an Operator in the Marine Corps. Soon thereafter, he acquired his father’s book of business along with a number of other agencies, consolidating them under the Bobby Brock name in honor of his father. Today, Bobby Brock Insurance is setting the industry standard. In 2023, it was named to the prestigious Inc. 5000 list as one of the fastest-growing private companies by revenue in the United States. The company has also won multiple industry awards for its one-stop insurance agency solution, GoGuru, and has become prolific in its use of social media to promote and foster the sharing of information between agents and brokers. “Our industry needs agents and brokers to focus on consumers’ needs first,” said Justin Brock. “If we can work towards an environment that rewards quality outcomes while creating efficiencies that allow our sales representatives to replicate the process often and with ease, we can prove that there is no better distribution model than through licensed life and health insurance agents. We are confident that our synergies with AmeriLife, SRG, and CPI will amplify our ability to achieve that goal.” Camas Prairie Insurance, a family-run, health brokerage established in 1996 by Dominic and Gina Lustig, primarily focuses on the Medicare and health insurance market. The company has experienced rapid growth over the past several years under the leadership of owner and CEO Josh Lustig, building upon a foundation centered on its “just do the next right thing” approach and an intense focus on educating clients on their health care needs. “This partnership is a watershed moment in Camas Prairie Insurance’s history,” said Josh Lustig, who is also the founder of Thrive, a personal and business development seminar program focused on helping agents grow their business. “I truly believe that, together, we are building something incomparable in our space for today’s individual agent and agency owner, and I couldn’t ask for better partners on this journey than Shane, Justin, Bobby Bache and the entire team at AmeriLife.” Now, as part of the AmeriLife family of companies, Bobby Brock Insurance and Camas Prairie Insurance will gain access to one of the industry’s largest independent health distribution platforms and a growing suite of products and solutions that is setting a standard for excellence in the industry. “Today is an incredible day for The Senior Resource Group and AmeriLife,” said Scotty Elliott, Chief Distribution Officer of Health for AmeriLife. “I couldn’t be more excited to welcome two companies of their reputation and caliber to our growing distribution network. Together, our opportunities for growth are limitless.” “One of the reasons I partnered with AmeriLife as an affiliate back in 2020 was for this very reason: to get to work with not only the best people in the industry, but people that have been my friends for years,” added Bobby Bache, vice president of Health Distribution for AmeriLife. “I’m thrilled to welcome Justin and Josh to AmeriLife and look forward to helping grow their respective businesses in new and exciting ways.” Bobby Brock Insurance and Camas Prairie Insurance will continue to operate as stand-alone businesses out of their Tupelo, Miss., and Grangeville, Idaho offices, respectively, under the leadership of Brock and Lustig, who will be supported by Souders. ### About The Senior Resource Group The Senior Resource Group was founded in 2008 by insurance brokers who understand the needs of agents in the field. Today, The Senior Resource Group is a premier field marketing organization for an array of national insurance carriers providing Medicare Supplement policies, Medicare Advantage plans, life insurance, final expanse plans and financial products in 25 states. The team at The Senior Resource Group provides the tools, support, and training necessary for success in the insurance industry. For more information, visit TheSeniorResourceGroup.com. About Bobby Brock Insurance Bobby Brock Insurance is a family-owned and operated insurance agency located in the heart of Tupelo, Mississippi. Founded by Bobby Brock in 1992, BBI has always been dedicated to providing top-quality insurance services in the community. The BBI team is made up of experienced, knowledgeable professionals who are passionate about helping clients find the coverage they need at a price they can afford with a personalized approach and commitment to customer service. For more information, visit BobbyBrockInsurance.com. About Camas Prairie Insurance Camas Prairie Insurance is an independent insurance agency that has been and is still devoted to overseeing the insurance needs of Grangeville, Idaho, for over 25 years. Camas Prairie Insurance is connected to a wide selection of carriers offering insurance programs and financial services which are readily available to residents of Grangeville. Camas Prairie is proud to provide insurance producers services to wade through paperwork, clarify policy options, design personalized plans, and supply the best coverage for our members’ needs. For more information, visit CamasPrairieInsurance.com. About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities, and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and financial professionals and more than 100 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado media@amerilife.com Partnership Inquiries Patrick Nichols corporatedevelopment@amerilife.com Company Website https://amerilife.com/

April 25, 2024 12:00 PM Eastern Daylight Time

Over 200 passionate programmers participated in The Bucharest Hackathon 2024, and the total prizes exceeded 50,000 dollars

STORM Partners

https://we.tl/t-lk7ZTXr33k Bucharest, 25th of April 2024: On April 14th, the Odeon Theater hosted the second edition of The Bucharest Hackathon, the first hackathon in Romania dedicated to enthusiasts of new technologies. The competition brought together over 200 amateur and senior programmers, both Romanian and foreign, who came from Bucharest as well as from other cities in the country, such as Cluj, Brasov, or Craiova. For 24 hours, they coded and competed in developing software projects that tested the limits of modern technologies. The top three teams won the grand prize of a total value of $30,000, but 25 teams were also selected to receive special prizes from the partners. For the final competition, 35 teams were selected. “ The Bucharest Hackathon is attracting more and more participants. I was impressed by the level of competence of the teams and projects and their achievements in only 24 hours. The jury members, most of whom have international experience, appreciated the location and organization, stating that they felt like they were at a hackathon in Silicon Valley. Genezio was chosen by more than half of the teams to implement their solution. ” Andrei Pitis, CEO & Co-founder of Genezio. “ From the moment we saw the first registrations for the event, we realized that we were going to have a completely different edition: an iconic location, much bolder ideas, much more creative solutions, but also a considerable effort - and so it was. The Bucharest Hackathon was truly an emotional roller-coaster: from the trust in the colleagues on our team to the transformation of an idea into a product, and to the decisive moment when you find out if you are among the winners,” said Flavian Manea, CEO and co-founder of Bware Labs. “At MultiversX, we are proud to support innovation and entrepreneurship in our tech community. The partnership with The Bucharest Hackathon underlines our commitment to the future of technology and innovation in Romania. We are excited to see such creative ideas turned into reality and provide the necessary support for these projects to become successful startups”, Daniel Serb, VP of Business Development of MultiversX. Each of the three winning teams received prizes worth over $10,000, as well as Amazon vouchers worth $15,000, while the teams that won special prizes from the partners received $20,000 in vouchers on the Blast platform, developed by Bware Labs, $10,000 in Genezio vouchers, two startup support prizes from MultiversX, a special prize from Google: Google Nest Hub (2nd Gen) smart speakers, an innovation prize from PiSquared worth $2,500 in vouchers and $2,000 in consulting vouchers from Astrarizon. Fork_Exec, Salty, and Awesome Hackers are this year's winning teams at The Bucharest Hackathon This year’s grand prize of $5,000 was won by the Fork_Exec team, made up of Dejanu Alexandru, Opri Cezar, and Dumitru Iulia. Fork_Exec developed a software solution based on speech recognition and artificial intelligence technologies that allows programmers to automate parts of coding based on voice commands. Second place, worth $3,000, went to the Salty team, composed of Kerimberdi Agayev Kaibov Merdan and Cihan Ilhan. They proposed an application for high school students to receive guidance on complex math problems. The application takes the user’s handwriting and, combining OpenAI and AWS Cloud technologies provides the answer to the problem almost instantly. The third prize, of $2,000, was won by the programmers from the Awesome Hackers team, namely Puiu Răzvan, Ene Cosmina, and Manea Lucas. Awesome Hackers created a neural data collection platform designed to help improve cognitive function and focus. In addition, two of the participating teams will receive support from MultiversX so that their ideas can reach the startup stage (Awesome Hackers and Mental Regression). Among the special prize winners is also the Wildcard team, who received a Nest Hub 2nd Generation from Google. The jury was made up of tech experts, IT entrepreneurs, and top executives from the companies: Genezio, Bware Labs, MultiversX, Google, Stripe, PiSquared, XOXNO, and Amazon Web Services. For this edition, the main partners Genezio and Bware Labs, the co-founding companies of The Bucharest Hackathon project, were joined by the Romanian blockchain company MultiversX. Among the partners of the second edition of The Bucharest Hackathon are the companies Stripe, PiSquared, XOXNO, Google, Amazon Web Services, Astrarizon, and xExchange. The event was sponsored by Orange Romania, AQUA Carpatica, Blue Romania, Domeniile Averești, Komoder Romania, Nespresso Professional, and Good Routine by SECOM, with media and communication partners Republica, Innovation Labs, ETH Bucharest, Caracteristic PR, KCD Romania, and the Student League Electronics. About The Bucharest Hackathon The Bucharest Hackathon is a 24-hour competition dedicated to programmers and enthusiasts of modern technologies, such as AI, Dev Tools, blockchain, and others. Although initially dedicated to those in Bucharest, the event welcomed programmers from other cities or countries in both editions. The event was founded by Bware Labs and Genezio in 2023 to provide enthusiasts of modern technologies with the space, resources, and challenges they need to develop themselves and test both their limits and those of new technologies. About MultiversX MultiversX is a highly scalable, secure, and decentralized blockchain network built from first principles, to solve the two fundamental problems critical for widespread, global adoption: a transition from dialup to broadband, and a significant UX paradigm shift. Media Contact: Dan Voicu, Head of Communications dan.voicu@multiversx.com Distributed by STORM Partners. Contact Adrian Bono for interviews and quotes - adrian.bono@storm.partners or telegram @STORMPartners Contact Details MultiversX Dan Voicu, Head of Communications dan.voicu@multiversx.com Company Website https://multiversx.com/

April 25, 2024 11:07 AM Eastern Daylight Time

Petros Pharmaceuticals announces online distribution for lead ED product with Lemonaid Health

Petros Pharmaceuticals Inc

Petros Pharmaceuticals CEO Fady Boctor joined Steve Darling from Proactive to share exciting developments with Proactive, highlighting a new collaboration with Lemonaid Health, a prominent telemedicine provider and subsidiary of 23andMe. Through this collaboration, Lemonaid Health's telehealth platform will offer prescription STENDRA® (avanafil) in all strengths, expanding distribution and enhancing access for patients. Lemonaid Health's extensive reach, having treated over 200,000 patients with erectile dysfunction (ED) to date, positions Petros to serve a broader patient base across the United States effectively. In addition to the collaboration with Lemonaid Health, Boctor discussed the positive results of an initial cohort in Petros' self-selection study. This study compares the use of a Drug Facts Label (DFL) alone to a combination of DFL with a web app. The preliminary results suggest that while the DFL-alone approach may be insufficient for self-selection, the combination with the proposed technology significantly improves outcomes. This study serves as a precursor to Petros' pivotal Phase 2 study, initiated earlier this month, which aims to provide compelling evidence to the FDA. The pivotal study is designed to demonstrate that users can determine the appropriateness of STENDRA® (avanafil) without the need for a physician and prescription. These developments underscore Petros Pharmaceuticals' commitment to leveraging innovative solutions to improve patient access to essential medications and streamline healthcare delivery processes. Contact Details Proactive North America Proactive North America +1 604-688-8158 na-editorial@proactiveinvestors.com

April 25, 2024 10:20 AM Eastern Daylight Time

Video

Hoag Health System Selects PathAI and the AISight Image Management System to Support the Transition To Digital and AI-enabled Pathology

PathAI

PathAI, a leading precision pathology company, today announced that Hoag Health System, the leading health system in the southern California region, will adopt the AISight Image Management System (IMS) as their primary platform, powering their transition to digital pathology. The transition from analog, glass-slide-based pathology to digital pathology continues to accelerate across anatomic pathology, globally. This transition is in part driven by the availability of AI pathology tools that harness machine learning (ML) algorithms to augment and assist the pathologist interpretation. “The transition to digital pathology will unlock dramatic improvements in how care is provided to Hoag’s patients. By utilizing the most advanced image management system on the market with embedded algorithms, we expect to be able to deliver faster turnaround times to our physicians, more accurate and reproducible pathologist assessments, and expand our understanding of how biomarkers can drive optimal care decisions,” said Dr. Michael Brant-Zawadzki, MD, FACR, Hoag Vice President, Research Administration, CATALiST and Addiction. AISight 1 is a cloud-native intelligent enterprise workflow solution that is used by the world's leading laboratories and research centers to power their digital pathology workflows and AI applications. It serves as a central hub for case management, image management, and best-in-class artificial intelligence tools from PathAI and third-party partners, to enable a broad spectrum of histopathology use cases. “Together with our partners, we will continue to pursue our vision to improve patient outcomes with AI-powered technology,” said Eric Walk, MD, FCAP, Chief Medical Officer, PathAI. “We are excited to partner with forward-thinking industry leaders like Hoag who embrace the science of what machine learning algorithms can offer healthcare professionals and how those learnings can augment and empower the important work of pathologists.” According to Dr. John Cupp, MD, Director of Digital Pathology, Hoag Health System and PathAI Advisor, “Hoag is particularly excited to utilize PathAI’s ArtifactDetect algorithm that can improve pathology review, specifically to address pre-analytical factors that typically would delay pathologist review, as well as applying PathAI’s quantitative IHC scoring algorithms to support complex interpretation in PDL1 and HER2.” Importantly, PathAI will collaborate with Hoag and their laboratory information system (LIS) provider to build a bi-directional integration between AISight and their Epic Beaker LIS instance to ensure a fully integrated pathologist experience. “Computational pathology promises to unlock great potential for predictive biomarkers for patients with cancer,” said Dr. David R. Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute. “This is an exciting next step in Hoag’s digital transformation as we continue to look ahead towards healthcare innovations that offer continual advancements in patient care, treatment efficacy, and overall public health outcomes.” 1 AISight is For Research Use Only. Not for use in diagnostic procedures. About Hoag Hoag is a nonprofit, regional health care delivery system in Orange County, California. Delivering world-class, comprehensive, personalized care, Hoag consists of 1,800 top physicians, 16 urgent care facilities, 11 health & wellness centers, and two award-winning hospitals. Hoag offers a comprehensive blend of health care services that includes seven institutes providing specialized services in the following areas: cancer, digestive health, heart and vascular, neurosciences, spine, women’s health, and orthopedics through Hoag’s affiliate, Hoag Orthopedic Institute, which consists of an orthopedic hospital and four ambulatory surgical centers. Hoag is the highest ranked hospital in Orange County by U.S. News & World Report and the only OC hospital ranked in the Top 10 in California, as well as a designated Magnet® hospital by the American Nurses Credentialing Center (ANCC). For more information, visit hoag.org. About PathAI PathAI is the leading precision pathology company providing software and AI-enabled solutions to all pathologist stakeholders including laboratories, research institutions, and the biopharma industry. Developed with the input of hundreds of pathologists, PathAI’s digital pathology Image Management System, AISight, is the solution of choice for laboratories transitioning to digital workflows. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

April 25, 2024 10:00 AM Eastern Daylight Time

ECLYPSES USHERS IN NEW ERA OF CYBERSECURITY ASSURANCE WITH FIPS 140-3 VALIDATION OF ITS CRYPTOGRAPHIC LIBRARY

Eclypses Inc.

Eclypses, a leader in end-point data protection, today announced that it has successfully secured the Federal Information Processing Standard 140-3 (FIPS 140-3) validation. The Eclypses Cryptographic Library (ECL), which acts as a key component inside its Secure MTE Technology, successfully passed a series of tests conducted by an independent NIST-accredited laboratory. Eclypses is committed to providing its global customers with the most stringently reviewed technology to ensure their users’ data is protected. Secure MTE technology protects data at the application level, and provides endpoint verification, adhering to zero trust principles. "Customers operating in a world of exponential and ever-changing cyber threats need to have trust that their enterprise and customer data is protected,” said David Gomes, chief executive officer, Eclypses. “Attaining FIPS 140-3 certification acknowledges Eclypses' relentless pursuit of excellence in data security. This certification validates our commitment to robust security protocols and paves the way for enhanced trust and reliability for our customers and partners." About FIPS 140-3 Seen as the gold standard in data security, FIPS 140-3 validation proves that Eclypses’ Cryptographic Library effectively and consistently helps the Secure MTE Technology safeguard user data, ensuring that bad actors cannot access valuable information at any point during the data transmission process. FIPS 140-3 is a U.S. government computer security standard used to approve cryptographic modules and covers a wide range of potential applications. With this validation from a National Institute of Standards and Technology (NIST) approved testing laboratory, Eclypses Cryptographic Library (ECL) is now validated. ECL houses all cryptographic algorithms used by Eclypses’ patented Secure MTE technology. Secure MTE provides true end-to-end payload protection through every aspect of a network, regardless of the configuration, and ensures that in the event of a breach, attackers cannot use the data to cause harm. This technology is an added layer of security at a low latency, complementing existing cyber security protocols with real-time speeds. FIPS 140-3 validation gives Eclypses clients confidence that its technology is built upon the highest levels of trust and reliability. “This validation signals a company has completed a strict review process and received validation from one of the most highly regarded security standards bodies in the world,” said Jefferson Dance, chief innovation officer, Eclypses. “With the FIPS 140-3 validation, Eclypses can continue to deliver data security for its finance, healthcare, retail, and critical infrastructure clients.” In order to achieve FIPS 140-3 validation, cryptographic modules are subject to testing by NVLAP-accredited Cryptographic and Security Testing laboratories. The validation for Eclypses was performed by Penumbra Security, Inc. About Eclypses Eclypses sets the new standard for protecting the world’s most sensitive enterprise and customer data. Secure MTE® Technology delivers a transformative cyber security solution by replacing actual data with instantly obsolete, meaningless random streams of values. Even as threat vectors increase and network breaches proliferate, sensitive data is protected for its intended recipients and use. Eclypses was named Best Cybersecurity Solution in the FTF News Technology Innovations Awards in 2022 and 2023. For more information, please visit www.eclypses.com. Contact Details Racepoint Global Anna Halstead +1 617-624-3212 eclypses@racepointglobal.com

April 25, 2024 09:03 AM Eastern Daylight Time

1 ... 34 35 36 37 38 ... 299